Old Drugs, New Signals: What the Side-Effect Conversation Is Really Saying
The “side effect” conversation in pharma is getting louder—but the real story isn’t about adverse events. It’s about signal detection becoming strategy.
For years, the industry …

A drug patent isn’t “worth” what the market says—it’s worth what litigation lets you keep.
Most acquisition models treat a drug patent like a clean asset: forecast cash flows, discount them, assign a value, move on. But in real life, the patent isn’t j…

Most NDAs Don’t Fail on Science. They Fail on Strategy.
In pharma, we love to talk about molecules—mechanisms, trial design, endpoints, and the elegance of the data. But anyone who’s shepherded an NDA knows the uncomfortable truth: the submission is …

Two clocks. One drug. And a deadline that can’t be negotiated.
In pharma, timing isn’t just strategy—it’s survival.
A single product can be governed by two different clocks that start ticking at different moments: patent protection and FDA exclusivity….

Advil Dual Action, a pain relief medication combining ibuprofen and aspirin, is designed to provide fast and effective relief… https://www.Drugchatter.com/chat/61409/how-quickly-does-advil-dual-action-work/

Small molecules vs. biologics: the patent playbook changes—and so does the LOE strategy for generics and biosimilars.
Most IP conversations about “loss of exclusivity” start with a familiar assumption: if you know the reference product’s patent estate,…

Biopharma vendors don’t “win tenders” by being the best—they win by being the first to understand what’s about to change.
In Europe, the moment a drug approaches loss of exclusivity (LoE), the market doesn’t just get more competitive—it gets operationa…

Pharma doesn’t just “discover” new drugs. It monetizes old ones.
There’s a quiet business model reshaping global drug spending: take a molecule that’s already been proven, already manufactured, already understood—and then repackage it as something new….

Biopharma is entering a new kind of “cliff”—not just the patent cliff, but the operational cliff that comes with it.
When a blockbuster’s exclusivity ends, the market doesn’t simply get cheaper. It gets faster, noisier, and more competitive—especially …

Most pharma teams don’t lose patent value because they miss deadlines—they lose it because they pick the wrong “one-shot.”
In drug development, timing is everything. But in patent strategy, timing is also choice architecture: which patent you anchor …